About
Qrons is a biotechnology company dedicated to developing biotech products, treatments and technologies that create a platform to combat neuronal diseases. Its approach seeks to marshal and leverage the remarkable advances made in the fields of artificial intelligence (AI), machine learning (ML), molecular biology, stem cells and tissue engineering, for deployment in the fight against neuronal diseases.
The company has two product candidates for treating traumatic brain injuries, both integrating proprietary, modified mesenchymal stem cells (MSCs) and smart synthetic material. QS100 is an injury-specific, 3D-printable, implantable MSC-synthetic hydrogel for treating penetrating brain injuries. QS200 is an injectable MSC-synthetic hydrogel for the treatment of concussions.
The company conducts its research in Israel under service agreements with Ariel University and has an ongoing sponsored research agreement with Dartmouth College.
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What was a significant corporate development for Qrons in February 2025?
- In February 2025, First Person and Qrons completed a merger, resulting in a publicly traded company focused on cognitive wellness and functional beverages.
- What was the nature of the agreement Qrons signed with First Person Ltd. in October 2024?
- In October 2024, First Person Ltd. signed a letter of intent to acquire Qrons Inc. through a reverse merger transaction.
- What new research program did Qrons announce in November 2023?
- In November 2023, Qrons announced the addition of Professor Shiri Navon-Venezia to its Scientific Advisory Board as part of a new sepsis research program.
- What intellectual property development did Qrons announce in August 2023?
- In August 2023, Qrons announced the filing of a provisional patent application related to its neuronal and infectious disease treatments development, including sepsis.
- What type of agreement did Qrons sign in July 2023 for a new research program?
- In July 2023, Qrons signed a license agreement term sheet for a new research program to experiment with and commercialize the therapeutic effect of certain Tellurium Based Compounds on antibiotic-resistant bacterial infections, sepsis, and traumatic brain injuries.
- What patent application did Qrons file in March 2023?
- In March 2023, Qrons filed the U.S. National Phase of its patent application for therapeutic polypseudorotaxane hydrogels, related to its QS200 product candidate.
- What new pre-clinical research program did Qrons announce in December 2022?
- In December 2022, Qrons announced a new pre-clinical research program to test the efficacy of Tellurium Based Compounds, either in combination with its QS200 product candidate or independently, for treating diffused axonal injuries and antibiotic-resistant bacteria and sepsis.
- What significant license was granted to Qrons by Dartmouth College in October 2019?
- In October 2019, Qrons was granted an exclusive world-wide license by Dartmouth College for intellectual property related to 3D printable materials in human and animal health.
- When did Qrons complete a successful in-vivo experiment for its QS100 product candidate?
- In January 2019, Qrons completed a successful in-vivo experiment with its QS100 candidate product for treating penetrating brain injuries in an animal model.
- What was Qrons' initial public listing event?
- Qrons became public on the OTC exchange in August 2017.